InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,415.39
(
1.33%
)
US TECH 100
18,392.80
(
1.87%
)
Dow Jones
39,691.18
(
0.85%
)
Brent Oil
80.47
(
-1.40%
)
Bitcoin
59,928.52
(
0.97%
)
Post# of 252867
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 835
Posts 120262
Boards Moderated 18
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 133476

Wednesday, 12/21/2011 2:15:10 PM

Wednesday, December 21, 2011 2:15:10 PM

Post# of 252867
Clarification on Teva’s 2012 Copaxone forecast: Insofar as Teva’s corporate style does not allow an admission that Teva might lose the patent case, Teva did not qualify its Copaxone forecast according to whether a generic version launches in the US market.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up